The rollator industry is overdue for a transformation, says columnist Dagmar Munn, a longtime user of the device who is living with ALS.

A study is exploring why athletes, first responders, and other high performers face an increased risk of developing ALS.

The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.

A bipartisan team of U.S. lawmakers has reintroduced the ALS Better Care Act, aimed at improving access to quality medical ...

Scientists developed a technique to grow cells that control voluntary movement, a discovery that could aid ALS and spinal ...

Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166 ...

Origami is collaborating with Ipsen to develop molecules designed to remove or correct abnormal proteins in neurodegenerative diseases.

A viral infection can trigger a neurological disease similar to amyotrophic lateral sclerosis (ALS) in mice with a specific ...

Coya Therapeutics raised $11.1 million to support manufacturing scale-up for its experimental ALS therapy, COYA 302.

Watching dancers capture both grief and joy reminded columnist Kristin Neva of her own life as a caregiver to her husband, who has ALS.

Reducing RAD23A levels helped nerve cells better handle toxic TDP-43 protein clumps, improving survival and function in an ALS mouse model.

U.S. clinical trials for ALS do not include enough non-white patients and women to reflect the disease's real-world prevalence, per a study.